{
}
Johnson & Johnson (NYSE: JNJ) reported a quarterly EPS of $2.77, exceeding estimates, with revenue of $21.89 billion. The company declared a quarterly dividend of $1.30 per share, marking an increase from the previous $1.24, and has a current market cap of $375.56 billion. Analysts maintain a "Moderate Buy" rating, with a consensus target price of $171.82.
Deutsche Bank has raised its price target for Kenvue Inc. to $23 from $22. Kenvue is a leading player in consumer healthcare, offering a diverse range of products across self-care (41.8% of sales), personal care (29.9%), and beauty and skin care (28.3%). The company's sales are primarily concentrated in North America (49.3%), followed by Europe-Middle East-Africa (21.9%), Asia-Pacific (20.1%), and Latin America (8.7%).
Israel is a leader in the global medical device industry, with significant advancements in imaging systems, surgical robots, and diagnostics. In 2023, 70 life sciences startups emerged, with 27 focused on medical devices, contributing to $1.4 billion in exits and IPOs, despite ongoing challenges. The country’s unique blend of immigration, military experience, and regulatory expertise fosters a robust innovation ecosystem, supported by strong academic-industry integration and substantial R&D investment.
UBS has reaffirmed its Buy rating for Johnson & Johnson, setting a price target of $180, despite challenges from talc-related lawsuits. Analysts are optimistic about the company's core business and growth in prescriptions for Tremfya, particularly with upcoming approvals for Crohn's disease and ulcerative colitis treatments.RBC Capital Markets also maintains an Outperform rating with a $181 target, highlighting the potential of RYBREVANT and LAZCLUZE in the lung cancer market. Moody's has affirmed Johnson & Johnson's strong financial position, noting its ability to manage legal liabilities effectively.
UBS has reiterated its Buy rating for Johnson & Johnson, setting a target price of $180, despite challenges from talc lawsuits. Analysts are optimistic about the company's core business, highlighting a 14% increase in prescriptions for Tremfya and potential approvals for new treatments. RBC Capital Markets also maintains an "Outperform" rating, emphasizing growth prospects in oncology, while Moody's affirms the company's strong financial position amid ongoing litigation.
UBS analyst Danielle Antalffy has reaffirmed a Buy rating on Johnson & Johnson (NYSE: JNJ) with a price target of $180.00. The positive outlook reflects confidence in the company's performance and potential for growth in the market.
UBS has reaffirmed its Buy rating and $180 price target for Johnson & Johnson, despite recent legal setbacks, including a federal judge's rejection of the company's bankruptcy strategy to settle talc-related lawsuits. The firm remains optimistic about the company's potential success in traditional litigation, as Johnson & Johnson explores alternative options. Additionally, the company reported promising results from its Phase 3 MARIPOSA study for lung cancer treatments and new data on nipocalimab for myasthenia gravis, highlighting its commitment to medical advancements amid ongoing legal challenges.
UBS analyst Danielle Antalffy has reaffirmed a Buy rating on Johnson & Johnson (NYSE: JNJ) with a price target of $180.00. The positive outlook reflects confidence in the company's performance and potential for growth in the market.
Kenvue Inc. reported a quarterly EPS of $0.26, meeting expectations, with a return on equity of 20.97% and a net margin of 6.66%. The company announced a quarterly dividend of $0.205, yielding 3.45%, while analysts maintain a "Hold" rating with an average target price of $24.00. Institutional investors own 97.64% of Kenvue's stock, reflecting strong market interest.
Kenvue Inc, a consumer health company, has 97.64% of its stock owned by institutional investors and hedge funds. Analysts have mixed ratings on the stock, with a consensus "Hold" and a price target of $24.00, while Barclays recently raised its target to $23.00. The company reported an EPS of $0.26, meeting expectations, and has a market cap of $44.95 billion.
Johnson & Johnson
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Johnson and Johnson reports strong earnings and increases quarterly dividend
11:49 05.05.2025
deutsche bank raises kenvue price target to twenty three dollars
14:22 24.04.2025
Israel's medical device sector thrives on innovation and regulatory expertise
03:30 10.04.2025
ubs maintains buy rating for johnson and johnson with strong growth prospects
17:40 04.04.2025
ubs maintains buy rating for johnson and johnson amid challenges and opportunities
17:35 04.04.2025
ubs maintains buy rating and price target for johnson and johnson
16:49 04.04.2025
ubs maintains buy rating for johnson and johnson amid legal challenges
16:00 01.04.2025
ubs maintains buy rating and price target for johnson and johnson
15:07 01.04.2025
Kenvue Inc reports steady earnings and announces quarterly dividend payout
10:28 31.03.2025
kenvue stock analysis institutional ownership and analyst ratings update
Royal Bank of Canada
Barclays PLC
Piper Sandler Cos
UBS Group AG
Johnson & Johnson
Citigroup Inc.
USA
Show more
14:47 28.03.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: